USFDA makes 22 observations post inspection of Lupin's Mandideep facilities
Lupin said the observations are "largely procedural in nature with some gaps identified in the aseptic processing areas of the Cephalosporin API block ” and the company is confident of addressing them satisfactorily.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Pharmaceuticals